Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

INM 005

Next Previous
Search
Drug Profile

INM 005

Alternative Names: Anti-SARS-CoV-2 hyperimmune equine immunoglobulin Fab2 fragment; Covifab; Equine hyperimmune serum - Inmunova; Hyperimmune anti-COVID-19 serum; Hyperimmune equine serum – Inmunova; INM-005

Latest Information Update: 21 Mar 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inmunova
  • Class Antibodies; Antivirals; Fab fragments; Polyclonal antibodies; Vaccines
  • Mechanism of Action Immunomodulators; Virus internalisation inhibitors; Virus replication inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered COVID 2019 infections
  • Research Haemolytic uraemic syndrome

Most Recent Events

  • 21 Mar 2024 Early research in Haemolytic uraemic syndrome (Prevention) in Argentina (IV), prior to March 2024 (Inmunova pipeline, March 2024)
  • 30 Dec 2020 Inmunova completes a phase II/III trial in COVID-2019 infections (In adults, In the elderly) in Argentina (IV) (NCT04494984)
  • 12 Dec 2020 Registered for COVID-2019 infections (In the elderly, In adults) in Argentina (IV)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top